Asset Acquisition, Maximum Aggregate Milestone Payments

No definition available.

Name:	cbio_AssetAcquisitionMaximumAggregateMilestonePayments
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Maximum Aggregate, Milestone Payments 1

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionMaximumAggregateMilestonePayments1
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Milestone Payment

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionMilestonePayment
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Milestone Payment, Research Plan Finalization

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionMilestonePaymentResearchPlanFinalization
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Non-Cash Upfront Consideration, Common Stock Issued

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionNonCashUpfrontConsiderationCommonStockIssued
Namespace Prefix:	cbio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Non-Cash Upfront Consideration, Common Stock Issued, Value

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionNonCashUpfrontConsiderationCommonStockIssuedValue
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Non-Cash Upfront Consideration, Common Stock Issued, Value Per Share

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionNonCashUpfrontConsiderationCommonStockIssuedValuePerShare
Namespace Prefix:	cbio_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Number Of Employees Overseeing And Coordinating Research Project

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionNumberOfEmployeesOverseeingAndCoordinatingResearchProject
Namespace Prefix:	cbio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Number Of Votes, Option Agreement

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionNumberOfVotesOptionAgreement
Namespace Prefix:	cbio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Option Agreement Expiration Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionOptionAgreementExpirationPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Option Agreement Sublicense Agreement Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionOptionAgreementSublicenseAgreementPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Option Agreement Termination Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionOptionAgreementTerminationPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Option Agreement Termination Period, Breach Of Contract

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionOptionAgreementTerminationPeriodBreachOfContract
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Option Agreement Termination Period, Maximum Contractual Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionOptionAgreementTerminationPeriodMaximumContractualPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Other Development Costs

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionOtherDevelopmentCosts
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Pre-Development Costs Incurred

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionPreDevelopmentCostsIncurred
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Research And Development Expense Accrued

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionResearchAndDevelopmentExpenseAccrued
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Research And Development Expense Incurred

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionResearchAndDevelopmentExpenseIncurred
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Research And Development Expense, Paid

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionResearchAndDevelopmentExpensePaid
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Royalty Percent Paid, Reduction Due To Invalid Patent

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionRoyaltyPercentPaidReductionDueToInvalidPatent
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Upfront Development Costs

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionUpfrontDevelopmentCosts
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Upfront Research And Development Cost Reimbursement

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionUpfrontResearchAndDevelopmentCostReimbursement
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Class Of Warrants Or Rights, Percent Of Outstanding Shares

+ References

No definition available.

+ Details

Name:	cbio_ClassOfWarrantsOrRightsPercentOfOutstandingShares
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cbio_LicenseAgreementAxis=cbio_ParagonOptionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cbio_ParagonTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR001Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cbio_ParagonTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cbio_ParascentHoldingLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR002Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR003Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Paragon Option Agreements - Narrative (Details) $ / shares in Units, $ in Thousands				1 Months Ended					3 Months Ended			6 Months Ended	12 Months Ended
	Sep. 26, 2025 USD ($)	Apr. 28, 2025 USD ($)	Mar. 18, 2025 USD ($)	Jan. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Nov. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) employee vote	Sep. 19, 2024 USD ($) $ / shares shares	Mar. 31, 2027	Mar. 31, 2026	Dec. 31, 2024 USD ($)	Sep. 30, 2025 USD ($) employee vote	Dec. 31, 2026	Dec. 31, 2025 USD ($)
Related Party
Asset Acquisition [Line Items]
Accounts payable and other current liabilities					$ 7,221						$ 7,221	$ 6,273
License Agreement Terms \| Paragon Option Agreements
Asset Acquisition [Line Items]
Number of employees overseeing and coordinating the project \| employee							2					2
Paragon Therapeutics \| Paragon Option Agreements
Asset Acquisition [Line Items]
Accounts payable and other current liabilities												$ 6,300
Paragon Therapeutics \| Paragon Option Agreements \| Forecast
Asset Acquisition [Line Items]
Percent of outstanding shares									1.00%	1.00%			1.00%	1.00%
Paragon Therapeutics \| Paragon Option Agreements \| Forecast \| Related Party
Asset Acquisition [Line Items]
Percent of outstanding shares											1.00%
Paragon Therapeutics \| License Agreement Terms \| Paragon Option Agreements
Asset Acquisition [Line Items]
Number of employees overseeing and coordinating the project \| employee							2					2
Number of votes \| vote							1					1
Option agreement termination period, maximum contractual period							30 days					30 days
Expiration period							30 days					30 days
Termination period							30 days					30 days
Research and development expense, paid				$ 3,300
Paragon Therapeutics \| License Agreement Terms \| Paragon Option Agreements \| Research and development
Asset Acquisition [Line Items]
Development costs incurred											$ 13,200
Paragon Therapeutics \| License Agreement Terms \| Paragon Option Agreements \| Related Party
Asset Acquisition [Line Items]
Accounts payable and other current liabilities					7,200						7,200
Paragon Therapeutics \| License Agreement Terms \| Paragon Option Agreements \| Related Party \| Research and development
Asset Acquisition [Line Items]
Development costs incurred											13,200
Paragon Therapeutics \| License Agreement Terms \| Paragon Option Agreements \| Related Party \| General and administrative
Asset Acquisition [Line Items]
Development costs incurred											100
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments			$ 22,000				$ 22,000
Milestone payment		$ 2,500
Percent reduction to royalty payment due to invalid patent												30.00%
Termination period due to breach of contract												60 days
Sublicense agreement period												30 days
Upfront research and development cost reimbursement						$ 1,500		$ 1,500
Research plan finalization payment					1,300
Milestone payment				$ 1,500
Research and development expense incurred											10,500
Research and development expense, paid											5,200
Research and development expense, accrued											600
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements \| Research and development
Asset Acquisition [Line Items]
Upfront development costs (less than)											1,500
Development costs incurred											4,600
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements \| General and administrative
Asset Acquisition [Line Items]
Upfront development costs (less than)											100
Development costs incurred											100
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements \| Related Party
Asset Acquisition [Line Items]
Non-refundable milestone payments											12,000
Accounts payable and other current liabilities					6,200						6,200
Milestone payment											10,000
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements \| Paragon Therapeutics
Asset Acquisition [Line Items]
Non-cash upfront consideration, common stock issued (in shares) \| shares								722,500
Non-cash upfront consideration, common stock, value per share (in dollars per share) \| $ / shares								$ 1.38
Non-cash upfront consideration, common stock issued, value								$ 1,000
Development costs incurred											4,700
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements \| Parascent Holding LLC
Asset Acquisition [Line Items]
Non-cash upfront consideration, common stock issued (in shares) \| shares								361,250
Paragon Therapeutics \| License Agreement Terms \| CR-001 \| Paragon Option Agreements \| Forecast
Asset Acquisition [Line Items]
Research and development expense, paid														$ 4,700
Paragon Therapeutics \| License Agreement Terms \| CR-002 \| Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments	$ 46,000						$ 46,000
Accounts payable and other current liabilities					800						800
Development costs incurred											800
Research plan finalization payment					$ 2,500
Pre-development costs incurred											0
Paragon Therapeutics \| License Agreement Terms \| CR-002 \| Paragon Option Agreements \| Research and development
Asset Acquisition [Line Items]
Development costs incurred											800
Paragon Therapeutics \| License Agreement Terms \| CR-002 \| Paragon Option Agreements \| General and administrative
Asset Acquisition [Line Items]
Development costs incurred											100
Paragon Therapeutics \| License Agreement Terms \| CR-002 \| Paragon Option Agreements \| Related Party
Asset Acquisition [Line Items]
Non-refundable milestone payments											26,000
Milestone payment											$ 20,000
Paragon Therapeutics \| License Agreement Terms \| CR-003 \| Paragon Option Agreements
Asset Acquisition [Line Items]
Non-refundable milestone payments		$ 46,000